# Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema

> **NCT00403039** · PHASE1 · COMPLETED · sponsor: **Vitreous -Retina- Macula Consultants of New York** · enrollment: 41 (actual)

## Conditions studied

- Retinal Vein Occlusion

## Interventions

- **DRUG:** Ranibizumab (Lucentis )

## Key facts

- **NCT ID:** NCT00403039
- **Lead sponsor:** Vitreous -Retina- Macula Consultants of New York
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2016-01-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00403039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00403039, "Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00403039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*